Black Diamond Therapeutics (BDTX)
Market Price (5/12/2026): $2.935 | Market Cap: $168.0 MilSector: Health Care | Industry: Biotechnology
Black Diamond Therapeutics (BDTX)
Market Price (5/12/2026): $2.935Market Cap: $168.0 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -60% Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Targeted Therapies, Personalized Diagnostics, and Biopharmaceutical R&D. | Weak multi-year price returns2Y Excs Rtn is -103%, 3Y Excs Rtn is -14% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -46 Mil Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is null, Rev Chg QQuarterly Revenue Change % is null Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -30% Key risksBDTX key risks include [1] an outsized dependency on its single lead candidate, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -60% |
| Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Targeted Therapies, Personalized Diagnostics, and Biopharmaceutical R&D. |
| Weak multi-year price returns2Y Excs Rtn is -103%, 3Y Excs Rtn is -14% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -46 Mil |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is null, Rev Chg QQuarterly Revenue Change % is null |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -30% |
| Key risksBDTX key risks include [1] an outsized dependency on its single lead candidate, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Black Diamond Therapeutics (BDTX) stock has gained about 20% since 1/31/2026 because of the following key factors:
1. Positive clinical advancements for silevertinib. Black Diamond Therapeutics announced an upcoming oral presentation of silevertinib Phase 2 data in frontline EGFRm NSCLC patients at the 2026 ASCO Annual Meeting, scheduled from May 29 to June 2, 2026. This presentation is expected to include preliminary Duration of Response (DOR) and Progression-Free Survival (PFS) data. Additionally, the company initiated a randomized Phase 2 trial of silevertinib in patients with newly diagnosed EGFRvIII+ Glioblastoma (GBM) by dosing the first patient in May 2026. Silevertinib has previously demonstrated a 60% confirmed objective response rate (cORR) and an 86% intracranial cORR in non-small cell lung cancer patients with non-classical EGFR mutations.
2. Robust financial runway with reduced operating expenses. As of March 31, 2026, Black Diamond Therapeutics reported cash, cash equivalents, and investments totaling $118.3 million, which is projected to be sufficient to fund its operations into the second half of 2028. The company also demonstrated a reduction in operating expenses, with research and development (R&D) expenses decreasing to $7.0 million in Q1 2026 from $10.5 million in Q1 2025, and general and administrative (G&A) expenses falling to $4.3 million from $5.0 million in the same period, reflecting operational efficiencies and a focused strategy on silevertinib.
Show more
1. Positive clinical advancements for silevertinib. Black Diamond Therapeutics announced an upcoming oral presentation of silevertinib Phase 2 data in frontline EGFRm NSCLC patients at the 2026 ASCO Annual Meeting, scheduled from May 29 to June 2, 2026. This presentation is expected to include preliminary Duration of Response (DOR) and Progression-Free Survival (PFS) data. Additionally, the company initiated a randomized Phase 2 trial of silevertinib in patients with newly diagnosed EGFRvIII+ Glioblastoma (GBM) by dosing the first patient in May 2026. Silevertinib has previously demonstrated a 60% confirmed objective response rate (cORR) and an 86% intracranial cORR in non-small cell lung cancer patients with non-classical EGFR mutations.
2. Robust financial runway with reduced operating expenses. As of March 31, 2026, Black Diamond Therapeutics reported cash, cash equivalents, and investments totaling $118.3 million, which is projected to be sufficient to fund its operations into the second half of 2028. The company also demonstrated a reduction in operating expenses, with research and development (R&D) expenses decreasing to $7.0 million in Q1 2026 from $10.5 million in Q1 2025, and general and administrative (G&A) expenses falling to $4.3 million from $5.0 million in the same period, reflecting operational efficiencies and a focused strategy on silevertinib.
Show more
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 18.1% change in BDTX stock from 1/31/2026 to 5/11/2026 was primarily driven by a 9.2233720368547763E17% change in the company's P/S Multiple.| (LTM values as of) | 1312026 | 5112026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.49 | 2.94 | 18.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 70 | 0 | |
| P/S Multiple | 2.0 | ∞ | 9.2233720368547763E17% |
| Shares Outstanding (Mil) | 57 | 57 | -0.5% |
| Cumulative Contribution | 0.0% |
Market Drivers
1/31/2026 to 5/11/2026| Return | Correlation | |
|---|---|---|
| BDTX | 18.1% | |
| Market (SPY) | 3.6% | 51.6% |
| Sector (XLV) | -7.2% | 36.7% |
Fundamental Drivers
The -24.0% change in BDTX stock from 10/31/2025 to 5/11/2026 was primarily driven by a null change in the company's Total Revenues ($ Mil).| (LTM values as of) | 10312025 | 5112026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.87 | 2.94 | -24.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 70 | 0 | |
| P/S Multiple | 3.1 | ∞ | 9.2233720368547763E17% |
| Shares Outstanding (Mil) | 57 | 57 | -0.8% |
| Cumulative Contribution | 0.0% |
Market Drivers
10/31/2025 to 5/11/2026| Return | Correlation | |
|---|---|---|
| BDTX | -24.0% | |
| Market (SPY) | 5.5% | 41.2% |
| Sector (XLV) | -0.0% | 28.1% |
Fundamental Drivers
The 72.9% change in BDTX stock from 4/30/2025 to 5/11/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 4302025 | 5112026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.70 | 2.94 | 72.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 57 | 57 | -1.1% |
| Cumulative Contribution | 0.0% |
Market Drivers
4/30/2025 to 5/11/2026| Return | Correlation | |
|---|---|---|
| BDTX | 72.9% | |
| Market (SPY) | 30.4% | 43.9% |
| Sector (XLV) | 3.6% | 31.4% |
Fundamental Drivers
The 105.6% change in BDTX stock from 4/30/2023 to 5/11/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 4302023 | 5112026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.43 | 2.94 | 105.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 36 | 57 | -36.4% |
| Cumulative Contribution | 0.0% |
Market Drivers
4/30/2023 to 5/11/2026| Return | Correlation | |
|---|---|---|
| BDTX | 105.6% | |
| Market (SPY) | 78.7% | 20.2% |
| Sector (XLV) | 12.6% | 12.9% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| BDTX Return | -83% | -66% | 56% | -24% | 14% | 23% | -91% |
| Peers Return | -4% | -17% | 24% | 2% | 59% | 24% | 101% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 8% | 97% |
Monthly Win Rates [3] | |||||||
| BDTX Win Rate | 25% | 25% | 50% | 42% | 67% | 60% | |
| Peers Win Rate | 53% | 53% | 60% | 50% | 65% | 56% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| BDTX Max Drawdown | -84% | -76% | -25% | -24% | -42% | -16% | |
| Peers Max Drawdown | -26% | -38% | -29% | -27% | -29% | -10% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: RVMD, INCY, EXEL, RLAY, IDYA.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/11/2026 (YTD)
How Low Can It Go
| Event | BDTX | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -47.3% | -18.8% |
| % Gain to Breakeven | 89.6% | 23.1% |
| Time to Breakeven | 55 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -11.1% | -7.8% |
| % Gain to Breakeven | 12.5% | 8.5% |
| Time to Breakeven | 6 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -51.2% | -9.5% |
| % Gain to Breakeven | 104.8% | 10.5% |
| Time to Breakeven | 96 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -53.8% | -6.7% |
| % Gain to Breakeven | 116.3% | 7.1% |
| Time to Breakeven | 109 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -77.4% | -24.5% |
| % Gain to Breakeven | 341.7% | 32.4% |
| Time to Breakeven | 257 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -51.2% | -33.7% |
| % Gain to Breakeven | 105.0% | 50.9% |
| Time to Breakeven | 37 days | 140 days |
In The Past
Black Diamond Therapeutics's stock fell -47.3% during the 2025 US Tariff Shock. Such a loss loss requires a 89.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | BDTX | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -47.3% | -18.8% |
| % Gain to Breakeven | 89.6% | 23.1% |
| Time to Breakeven | 55 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -51.2% | -9.5% |
| % Gain to Breakeven | 104.8% | 10.5% |
| Time to Breakeven | 96 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -53.8% | -6.7% |
| % Gain to Breakeven | 116.3% | 7.1% |
| Time to Breakeven | 109 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -77.4% | -24.5% |
| % Gain to Breakeven | 341.7% | 32.4% |
| Time to Breakeven | 257 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -51.2% | -33.7% |
| % Gain to Breakeven | 105.0% | 50.9% |
| Time to Breakeven | 37 days | 140 days |
In The Past
Black Diamond Therapeutics's stock fell -47.3% during the 2025 US Tariff Shock. Such a loss loss requires a 89.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Black Diamond Therapeutics (BDTX)
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
AI Analysis | Feedback
Loxo Oncology for complex cancer mutations.
Vertex Pharmaceuticals, but for precision cancer drugs.
AI Analysis | Feedback
- BDTX-189: An irreversible small molecule inhibitor designed to target oncogenic proteins defined by non-canonical EGFR and HER2 driver mutations.
- BDTX-1535: A brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations.
- BDTX-4933: A brain-penetrant inhibitor of oncogenic BRAF class I, II, and III alterations.
AI Analysis | Feedback
Black Diamond Therapeutics (BDTX) is a biotechnology company that discovers, develops, and commercializes medicines for patients with genetically defined tumors. While the company's current pipeline consists of drug candidates in various stages of development, its business model involves the eventual commercialization of these medicines.
Once its medicines are approved and commercialized, Black Diamond Therapeutics would primarily sell to other companies within the pharmaceutical supply chain. The major customers in this scenario would typically include:
- Pharmaceutical Wholesalers and Distributors: These companies purchase medicines in bulk directly from manufacturers and distribute them to pharmacies, hospitals, and clinics. Examples of major public companies in this sector include:
- McKesson Corporation (MCK)
- AmerisourceBergen Corporation (ABC)
- Cardinal Health, Inc. (CAH)
- Hospitals and Integrated Delivery Networks (IDNs): Large hospital systems or healthcare networks may purchase certain specialized or hospital-administered drugs directly from the manufacturer.
- Specialty Pharmacies: For highly targeted or complex oncology drugs, specialty pharmacies often serve as key distribution and patient support partners.
AI Analysis | Feedback
- Cadence Design Systems, Inc. (CDNS)
AI Analysis | Feedback
Mark Velleca, M.D., Ph.D., Chief Executive Officer, President and Chairman
Mark Velleca was appointed CEO of Black Diamond Therapeutics in September 2023, having previously served as Chairman of the Board since 2022 and as a board member since 2021. Prior to joining Black Diamond, Dr. Velleca was the CEO of G1 Therapeutics, Inc., where he successfully led the company through its initial public offering and guided the development of its first therapy, COSELA®, from investigational new drug (IND) filing to U.S. Food and Drug Administration (FDA) approval. He also served as CEO of StrideBio, a gene therapy company, and was a Venture Partner at Hatteras Venture Partners.
Erika Jones, Principal Financial Officer and Principal Accounting Officer
Erika Jones was appointed Principal Financial Officer and Principal Accounting Officer of Black Diamond Therapeutics effective October 7, 2024. She previously held the position of Senior Vice President of Finance and Corporate Controller within the company.
Elizabeth Buck, Ph.D., Co-Founder and Chief Scientific Officer
Elizabeth Buck is a co-founder of Black Diamond Therapeutics. She currently serves as the Chief Scientific Officer, and is involved in presenting at investor conferences alongside the CEO.
Sergey Yurasov, M.D., Ph.D., Chief Medical Officer
Sergey Yurasov serves as the Chief Medical Officer of Black Diamond Therapeutics.
Brent Hatzis-Schoch, Esq., J.D., Chief Operating Officer and General Counsel
Brent Hatzis-Schoch holds the roles of Chief Operating Officer and General Counsel at Black Diamond Therapeutics.
AI Analysis | Feedback
The key risks to Black Diamond Therapeutics (BDTX) business are primarily centered around the successful development and commercialization of its lead drug candidate, its ongoing need for substantial funding, and the protection of its intellectual property.Key Risks for Black Diamond Therapeutics (BDTX)
- Clinical Development and Regulatory Risks: Black Diamond Therapeutics is heavily reliant on the successful clinical development, regulatory approval, and eventual commercialization of its primary product candidate, BDTX-1535 (also referred to as silevertinib). Failures, delays, or unexpected adverse events in ongoing clinical trials for BDTX-1535 in indications such as EGFR-mutant Non-Small Cell Lung Cancer (NSCLC) and glioblastoma, or an inability to secure regulatory approvals, would severely impact the company's business. The oncology market, particularly for EGFR inhibitors, is highly competitive, requiring BDTX-1535 to demonstrate significant efficacy to establish a market position.
- Funding and Liquidity Risks: As a clinical-stage biotechnology company, Black Diamond Therapeutics has a history of incurring substantial operating losses and anticipates continued losses for the foreseeable future. Despite recent financial maneuvers that have extended its cash runway, the company will require significant additional capital to sustain its operations and advance its drug development programs into later stages and potential commercialization. Difficulties in raising this additional capital on favorable terms could force the company to delay, scale back, or even discontinue its development efforts.
- Intellectual Property Protection Risks: The ability of Black Diamond Therapeutics to compete and generate revenue is critically dependent on its capacity to obtain, maintain, and enforce robust patent and other intellectual property protections for BDTX-1535 and its underlying drug discovery platform. Any failure to adequately protect its intellectual property could allow competitors to develop and commercialize similar or identical products, thereby eroding Black Diamond Therapeutics' competitive advantage and future revenue potential.
AI Analysis | Feedback
nullAI Analysis | Feedback
nullAI Analysis | Feedback
Here are 3 expected drivers of future revenue growth for Black Diamond Therapeutics (BDTX) over the next 2-3 years:
- Strategic Partnerships and Milestone Payments for BDTX-1535 (Silevertinib) in NSCLC: Black Diamond Therapeutics is actively pursuing global partnership opportunities for its lead candidate, silevertinib (BDTX-1535), specifically for non-small cell lung cancer (NSCLC) with non-classical EGFR mutations. Key clinical data, including durability of response (DOR) and progression-free survival (PFS), are anticipated in the second quarter of 2026, which are crucial for attracting and finalizing such collaborations. Discussions with the FDA regarding pivotal trial design are also planned for the first half of 2026. Successful partnerships would likely include upfront payments and subsequent milestone payments triggered by further development, regulatory achievements, and commercialization progress, tapping into a potential $2 billion market opportunity in frontline EGFR lung cancer.
- Milestone Payments from the BDTX-4933 Licensing Agreement with Servier: In March 2025, Black Diamond Therapeutics entered into a global licensing agreement with Servier Pharmaceuticals for BDTX-4933, which generated a significant upfront payment. While this initial payment was a one-time event, such strategic partnerships typically include additional milestone payments tied to specific development, regulatory, and commercial progress by the licensee, Servier. These future milestone payments would contribute to Black Diamond's revenue stream over the next few years as BDTX-4933 advances.
- Advancement of BDTX-1535 (Silevertinib) in Glioblastoma (GBM) Leading to Potential Collaboration Opportunities: The company is advancing silevertinib into a Phase 2 trial for newly diagnosed glioblastoma patients with EGFR alterations, leveraging the drug's potent activity against EGFRvIII and high brain penetrance. Initial data from this Phase 2 GBM trial is expected in the first half of 2028. Positive clinical data in this indication could attract further collaborations or licensing deals, leading to potential milestone payments and contributing to future revenue growth within or shortly after the specified 2-3 year timeframe.
AI Analysis | Feedback
```htmlShare Issuance
- Black Diamond Therapeutics' non-employee directors received common stock as compensation for annual board service, including 5,208 shares and 4,665 shares on December 12, 2025, both valued at $2.76 per share.
- Stock options were granted to executives on January 21, 2026, including 250,000 options to the Chief Scientific Officer, 250,000 options to the Chief Medical Officer, and 600,000 options to the President and CEO, all with an exercise price of $2.57 per share.
- As of Q3 2025, the company had 57 million shares outstanding, an increase of 0.1% from the prior quarter.
Inbound Investments
- In March 2025, Black Diamond Therapeutics entered a global licensing agreement with Servier Pharmaceuticals LLC for BDTX-4933.
- This agreement included an upfront payment of $70 million to Black Diamond Therapeutics.
- The company is eligible for potential development and commercial sales milestone payments up to $710 million, along with tiered royalties on global net sales from the Servier deal.
Capital Expenditures
- Black Diamond Therapeutics reported $0 in capital expenditures in Q3 2024.
- As of September 30, 2025, the company had approximately $135.5 million in cash, cash equivalents, and investments, which is projected to fund operating expenses and capital expenditure requirements into Q4 2027.
- The company has focused on optimizing operations and reducing expenses, with research and development (R&D) expenses decreasing to $7.4 million in Q3 2025 from $12.9 million in Q3 2024, to focus on the development of BDTX-1535.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Black Diamond Therapeutics Earnings Notes | 12/16/2025 | |
| Would You Still Hold Black Diamond Therapeutics Stock If It Fell Another 30%? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to BDTX.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 38.92 |
| Mkt Cap | 7.7 |
| Rev LTM | 118 |
| Op Inc LTM | -115 |
| FCF LTM | -61 |
| FCF 3Y Avg | -97 |
| CFO LTM | -60 |
| CFO 3Y Avg | -95 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 21.5% |
| Rev Chg 3Y Avg | 480.3% |
| Rev Chg Q | -25.5% |
| QoQ Delta Rev Chg LTM | 2.4% |
| Op Inc Chg LTM | 19.6% |
| Op Inc Chg 3Y Avg | -29.7% |
| Op Mgn LTM | -27.2% |
| Op Mgn 3Y Avg | -1,034.1% |
| QoQ Delta Op Mgn LTM | -3.8% |
| CFO/Rev LTM | -4.9% |
| CFO/Rev 3Y Avg | -766.4% |
| FCF/Rev LTM | -6.3% |
| FCF/Rev 3Y Avg | -780.5% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 7.7 |
| P/S | 8.2 |
| P/Op Inc | -5.7 |
| P/EBIT | -5.7 |
| P/E | -6.2 |
| P/CFO | -7.9 |
| Total Yield | -5.2% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -8.1% |
| D/E | 0.0 |
| Net D/E | -0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 8.4% |
| 3M Rtn | 22.2% |
| 6M Rtn | 7.4% |
| 12M Rtn | 74.7% |
| 3Y Rtn | 54.6% |
| 1M Excs Rtn | -0.4% |
| 3M Excs Rtn | 15.7% |
| 6M Excs Rtn | -1.7% |
| 12M Excs Rtn | 40.1% |
| 3Y Excs Rtn | -22.3% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Development of MasterKey therapies that target families of oncogenic mutations in patients with | 0 | ||||
| Total | 0 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Development of MasterKey therapies that target families of oncogenic mutations in patients with | -70 | ||||
| Total | -70 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Development of MasterKey therapies that target families of oncogenic mutations in patients with | 159 | 156 | 248 | 330 | |
| Total | 159 | 156 | 248 | 330 |
Price Behavior
Price Behavior
| Market Price | $2.94 | |
| Market Cap ($ Bil) | 0.2 | |
| First Trading Date | 01/30/2020 | |
| Distance from 52W High | -39.6% | |
| 50 Days | 200 Days | |
| DMA Price | $2.51 | $2.94 |
| DMA Trend | indeterminate | up |
| Distance from DMA | 17.0% | 0.0% |
| 3M | 1YR | |
| Volatility | 71.0% | 74.2% |
| Downside Capture | 1.20 | 1.60 |
| Upside Capture | 329.90 | 295.35 |
| Correlation (SPY) | 42.4% | 41.6% |
BDTX Betas & Captures as of 4/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.13 | 2.31 | 2.37 | 2.25 | 2.63 | 2.12 |
| Up Beta | 0.97 | 1.19 | 1.40 | 2.58 | 1.84 | 1.79 |
| Down Beta | -4.42 | 1.13 | 1.35 | 1.45 | 1.71 | 1.67 |
| Up Capture | 356% | 392% | 410% | 230% | 1021% | 2914% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 13 | 21 | 33 | 60 | 125 | 345 |
| Down Capture | 420% | 262% | 244% | 210% | 195% | 113% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 9 | 21 | 30 | 60 | 116 | 385 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BDTX | |
|---|---|---|---|---|
| BDTX | 81.4% | 74.3% | 1.13 | - |
| Sector ETF (XLV) | 8.6% | 15.4% | 0.34 | 29.9% |
| Equity (SPY) | 28.1% | 12.5% | 1.78 | 42.4% |
| Gold (GLD) | 42.9% | 26.9% | 1.30 | 18.9% |
| Commodities (DBC) | 48.6% | 18.0% | 2.14 | -1.7% |
| Real Estate (VNQ) | 13.6% | 13.5% | 0.70 | 16.6% |
| Bitcoin (BTCUSD) | -22.4% | 41.7% | -0.50 | 28.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BDTX | |
|---|---|---|---|---|
| BDTX | -34.5% | 132.4% | 0.07 | - |
| Sector ETF (XLV) | 4.8% | 14.6% | 0.15 | 14.1% |
| Equity (SPY) | 12.9% | 17.1% | 0.59 | 20.7% |
| Gold (GLD) | 21.2% | 17.9% | 0.96 | 3.5% |
| Commodities (DBC) | 13.5% | 19.1% | 0.58 | -1.6% |
| Real Estate (VNQ) | 3.6% | 18.8% | 0.09 | 15.9% |
| Bitcoin (BTCUSD) | 8.5% | 56.0% | 0.36 | 9.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BDTX | |
|---|---|---|---|---|
| BDTX | -22.6% | 123.4% | 0.05 | - |
| Sector ETF (XLV) | 9.2% | 16.5% | 0.45 | 17.2% |
| Equity (SPY) | 15.0% | 17.9% | 0.72 | 22.8% |
| Gold (GLD) | 13.4% | 15.9% | 0.70 | 4.8% |
| Commodities (DBC) | 9.5% | 17.7% | 0.45 | 2.3% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.24 | 17.7% |
| Bitcoin (BTCUSD) | 68.1% | 66.9% | 1.07 | 11.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/16/2026 | 1.8% | -1.8% | 31.1% |
| 11/6/2025 | 2.8% | 25.8% | -28.9% |
| 8/7/2025 | -15.2% | 3.0% | 9.3% |
| 3/6/2025 | -1.1% | -13.2% | -26.3% |
| 11/5/2024 | 8.7% | 13.0% | -17.7% |
| 8/6/2024 | -5.6% | -11.7% | 6.0% |
| 3/12/2024 | -5.5% | 17.5% | 24.5% |
| 11/6/2023 | 0.5% | -6.3% | 19.5% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 11 | 10 | 10 |
| # Negative | 7 | 8 | 8 |
| Median Positive | 2.6% | 7.4% | 9.6% |
| Median Negative | -5.5% | -7.7% | -22.6% |
| Max Positive | 8.7% | 25.8% | 31.1% |
| Max Negative | -15.2% | -13.2% | -28.9% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 03/16/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/12/2025 | 10-Q |
| 12/31/2024 | 03/06/2025 | 10-K |
| 09/30/2024 | 11/05/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 03/12/2024 | 10-K |
| 09/30/2023 | 11/06/2023 | 10-Q |
| 06/30/2023 | 08/11/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 03/09/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.